AEON Biopharma, Inc. (AEON) stock
AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.15−0.01 (-3.59%)
Close on Nov 13, 2026Market cap $7.63MP/E –Yield –
AEON Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
AEON Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$19.78M. For fiscal 2025 it was -$12.73M, down 117.4% from the year before.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.73M | -117.4% |
| FY2024 | Dec 31, 2024 | $73.08M | – |
| FY2022 | Dec 31, 2022 | -$48.36M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.32M | -102.8% |
| Q1 FY2025 | Mar 31, 2025 | -$443.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.99M | – |
| Q2 FY2024 | Jun 30, 2024 | $153.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$74.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.00M | – |
See a number that looks wrong?